Biocon's product portfolio includes enzymes, small molecules, recombinant proteins, antibodies etc.
Bangalore-based Biocon has reported a jump of 24.85% in its consolidated net profit to Rs. 100 crore (Rs. 100.75 crore, to be precise) in the Q3FY11, from Rs 80.9 crore in the same quarter of the previous financial year i.e., Q3FY10.
Its consolidated net sales jumped 14.65% to Rs 728 crore from Rs 635 crore (y-o-y), while EBIDTA surged 34 per cent to Rs 178 crore, during the same period. The company’s EBIDTA margins stood at 24 per cent, during the quarter, reflecting improved quality of earnings. The company said that the strong growth momentum was led by strong showings in its branded formulations and statins businesses.
Commenting on the company’s results, Kiran Mazumdar Shaw, Chairman and Managing Director, said, “This marks an important growth milestone which will enable us to invest in advancing our research programs and expand our manufacturing and marketing partnerships, which we believe, are catalysts of growth for the future.”
Established in 1978, Biocon has risen to emerge as India's largest biotechnology company and amongst top 10 biotech firms, internationally.
For live chart: click here
No comments:
Post a Comment